{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:18:20Z","timestamp":1769595500039,"version":"3.49.0"},"reference-count":39,"publisher":"Japanese Society of Toxicology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Toxicol. Sci."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2131\/jts.40.33","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T09:17:55Z","timestamp":1418980675000},"page":"33-42","source":"Crossref","is-referenced-by-count":14,"title":["Fluvoxamine by itself has potential to directly induce long QT syndrome at supra-therapeutic concentrations"],"prefix":"10.2131","volume":"40","author":[{"given":"Yukiko","family":"Yamazaki-Hashimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Izumi-Nakaseko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"898","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Beach, S.R., Kostis, W.J., Celano, C.M., Januzzi, J.L., Ruskin, J.N., Noseworthy, P.A. and Huffman, J.C. (2014): Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J. Clin. Psychiatry., <b>75<\/b>, e441-449.","DOI":"10.4088\/JCP.13r08672"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Carlsson, L., Amos, G.J., Andersson. B., Drews, L., Duker, G. and Wadstedt, G. (1997): Electrophysiological characterization of the prokinetic agents cisapride and mosapride <i>in vivo<\/i> and <i>in vitro<\/i>: implications for proarrhythmic potential? J. Pharmacol. Exp. Ther., <b>282<\/b>, 220-227.","DOI":"10.1016\/S0022-3565(24)36775-8"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Claassen, V. (1983): Review of the animal pharmacology and pharmacokinetics of fluvoxamine. Br. J. Clin. Pharmacol., <b>15<\/b>, 349S-355S.","DOI":"10.1111\/j.1365-2125.1983.tb02125.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"de Boer, R.A., van Dijk, T.H., Holman, N.D. and van Melle, J.P. (2005): QT interval prolongation after sertraline overdose: a case report. BMC. Emerg. Med., <b>5<\/b>, 1-4. doi: 10.1186\/1471-227X-5-5","DOI":"10.1186\/1471-227X-5-5"},{"key":"5","doi-asserted-by":"crossref","unstructured":"de Wilde, J.E., Mertens, C. and Wakelin, J.S. (1983): Clinical trials of fluvoxamine vs chlorimipramine with single and three times daily dosing. Br. J. Clin. Pharmacol., <b>15<\/b>, 427S-431S.","DOI":"10.1111\/j.1365-2125.1983.tb02133.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"de Wilde, J.E.M. and Doogon, D.P. (1982): Fluvoxamine and chlorimipramine in endogenous depression. J. Affect. Disord., <b>4<\/b>, 249-259.","DOI":"10.1016\/0165-0327(82)90009-X"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Emoto, C., Murayama, N., Rostami-Hodjegan, A. and Yamazaki, H. (2009): Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: impact of plasma and microsomal binding. Xenobiotica., <b>39<\/b>, 227-235.","DOI":"10.1080\/00498250802668863"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Granfors, M.T., Backman, J.T., Neuvonen, M., Ahonen, J. and Neuvonen, P.J. (2004): Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. Clin. Pharmacol. Ther., <b>75<\/b>, 331-341.","DOI":"10.1016\/j.clpt.2003.12.005"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Guelfi, J.D., Dreyfus, J.F. and Pichot, P. (1983): A double-blind controlled clinical trial comparing fluvoxamine with imipramine. Br. J.Clin. Pharmacol., <b>15<\/b>, 411S-417S.","DOI":"10.1111\/j.1365-2125.1983.tb02131.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Ha\u00efssaguerre, M., Derval, N., Sacher, F., Jesel, L., Deisenhofer, I., de Roy, L., Pasqui\u00e9, J.L., Nogami, A., Babuty, D., Yli-Mayry, S., De Chillou, C., Scanu, P., Mabo, P., Matsuo, S., Probst, V., Le Scouarnec, S., Defaye, P., Schlaepfer, J., Rostock, T., Lacroix, D., Lamaison, D., Lavergne, T., Aizawa, Y., Englund, A., Anselme, F., O&apos;Neill, M., Hocini, M., Lim, K.T., Knecht, S., Veenhuyzen, G.D., Bordachar, P., Chauvin, M., Jais, P., Coureau, G., Chene, G., Klein, G.J. and Cl\u00e9menty, J. (2008): Sudden cardiac arrest associated with early repolarization. N. Engl. J. Med.,<b> 358<\/b>, 2016-2023.","DOI":"10.1056\/NEJMoa071968"},{"key":"11","unstructured":"Ishigooka, J., Wakatabe, H., Shimada, E., Suzuki, M., Fukuyama, Y., Murasaki, M. and Miura, S. (1993): Phase I trial on the serotonin reuptake inhibitor SME3110 (fluvoxamine maleate). Clin. Eval., <b>21<\/b>, 441-490."},{"key":"12","doi-asserted-by":"crossref","unstructured":"Kanjanauthai, S., Kanluen, T. and Chareonthaitawee, P. (2008): Citalopram induced torsade de pointes, a rare life threatening side effect. Int. J. Cardiol., <b>131<\/b>, e33-e34.","DOI":"10.1016\/j.ijcard.2007.08.006"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Kise, H., Nakamura, Y., Hoshiai, M., Sugiyama, H., Sugita, K. and Sugiyama, A. (2010): Cardiac and haemodynamic effects of tacrolimus in the halothane-anaesthetized dog. Basic. Clin. Pharmacol. Toxicol., <b>106<\/b>, 288-295.","DOI":"10.1111\/j.1742-7843.2009.00477.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Klok, C.J., Brouwer, G.J., Van Praag, H.M. and Doogan, D. (1981): Fluvoxamine and clomipramine in depressed patients. a double-blind clinical study. Acta. Psychiatr. Scand., <b>64<\/b>, 1-11.","DOI":"10.1111\/j.1600-0447.1981.tb00756.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Kogut, C., Crouse, E.B., Vieweg, W.V., Hasnain, M., Baranchuk, A., Digby, G.C., Koneru, J.N., Femandez, A., Deshmukh, A., Hancox, J.C. and Pandurangi, A.K. (2013): Selective serotonin reuptake inhibitors and torsade de pointes: new concepts and new directions derived from a systematic review of case reports. Ther. Adv. Drug. Saf., <b>4<\/b>, 189-198.","DOI":"10.1177\/2042098613492366"},{"key":"16","unstructured":"Manet, P., Hilpert, F., Fouet, P. and Tol\u00e9dano, D. (1993): Ventricular arrhythmia during fluvoxamine poisoning. Therapie., <b>48<\/b>, 62-63."},{"key":"17","doi-asserted-by":"crossref","unstructured":"Milnes, J.T., Crociani, O., Arcangeli, A., Hancox, J.C. and Witchel, H.J. (2003): Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br. J. Pharmacol., <b>139<\/b>, 887-898.","DOI":"10.1038\/sj.bjp.0705335"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Mitsumori, Y., Nakamura, Y., Hoshiai, K., Nagayama, Y., Adachi-Akahane, S., Koizumi, S., Matsumoto, M. and Sugiyama, A. (2010): <i>In vivo<\/i> canine model comparison of cardiovascular effects of antidepressants milnacipran and imipramine. Cardiovasc. Toxicol., <b>10<\/b>, 275-282.","DOI":"10.1007\/s12012-010-9084-9"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Nia, A.M., Dahlem, K.M., Gassanov, N., Hungerb\u00fchler, H., Fuhr, U. and Er, F. (2012): Clinical impact of fluvoxamine-mediated long QTU syndrome. Eur. J. Clin. Pharmacol., <b>68<\/b>, 109-111.","DOI":"10.1007\/s00228-011-1091-7"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Ohtani, H., Odagiri, Y., Sato, H., Sawada, Y. and Iga, T. (2001): A comparative pharmacodynamic study of the arrhythmogenicity of antidepressants, fluvoxamine and imipramine, in guinea pigs. Biol. Pharm. Bull.,<b> 24<\/b>, 550-554.","DOI":"10.1248\/bpb.24.550"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Okayasu, H., Ozeki, Y., Fujii, K., Takano, Y., Saeki, Y., Hori, H., Horie, M., Higuchi, T., Kunugi, H. and Shimoda, K. (2012): Pharmacotherapeutic determinants for QTc interval prolongation in Japanese patients with mood disorder. Pharmacopsychiatry, <b>45<\/b>, 279-283.","DOI":"10.1055\/s-0032-1308969"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Omori, I.M., Watanabe, N., Nakagawa, A., Akechi, T., Cipriani, A., Barbui, C., McGuire, H., Churchill, R. and Furukawa, T.A. (2009): Efficacy, tolerability and side-effect profile of fluvoxamine for major depression: meta-analysis. J. Psychopharmacol., <b>23<\/b>, 539-550.","DOI":"10.1177\/0269881108089876"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Pacher, P. and Kecskemeti, V. (2004): Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr. Pharm. Des., <b>10<\/b>, 2463-2475.","DOI":"10.2174\/1381612043383872"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Robinson, J.F. and Doogan, D.P. (1982): A placebo controlled study of the cardiovascular effects of fluvoxamine and clovoxamine in human volunteers. Br. J. Clin. Pharmacol.,<b> 14<\/b>, 805-808.","DOI":"10.1111\/j.1365-2125.1982.tb02040.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Rodriguez de la Torre, B., Dreher, J., Malevany, I., Bagli, M., Kolbinger, M., Omran, H., L\u00fcderitz, B. and Rao, M.L. (2001): Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther. Drug. Monit., <b>23<\/b>, 435-440.","DOI":"10.1097\/00007691-200108000-00019"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Roos, J.C. (1983): Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine. Br. J. Clin. Pharmacol., <b>15<\/b>, 439S-445S.","DOI":"10.1111\/j.1365-2125.1983.tb02135.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Saletu, B., Schjerve, M., Gr\u00fcnberger, J., Schanda, H. and Arnold, O.H. (1977): Fluvoxamine-a new serotonin re-uptake inhibitor: first clinical and psychometric experiences in depressed patients. J.Neural. Transm., <b>41<\/b>, 17-36.","DOI":"10.1007\/BF01252962"},{"key":"28","unstructured":"Sato, N., Takata, H., Tsukui, M., Tatebayashi, T., Fuji, K., Hiranuma, T., Aizawa, K. and Nakayoshi, T., (1995): Studies on the pharmacokinetics of fluvoxamine malate: plasma concentration profile and brain distribution in rats. Jpn. Pharmacol. Ther., <b>23<\/b>, 637-642."},{"key":"29","doi-asserted-by":"crossref","unstructured":"Singh, P. and Maldonado-Duran, J.M. (2014): Drug-induced QT prolongation as a result of an escitalopram overdose in a patient with previously undiagnosed congenital long QT syndrome. Case. Rep. Med., <b>2014<\/b>, 1-3 doi: 10.1155\/2014\/917846.","DOI":"10.1155\/2014\/917846"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Sugiyama, A. (2008): Sensitive and reliable proarrhythmia<i> in vivo<\/i> animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts. Br. J. Pharmacol., <b>154<\/b>, 1528-1537.","DOI":"10.1038\/bjp.2008.240"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Sugiyama, A. and Hashimoto, K. (1998): Effects of gastrointestinal prokinetic agents, TKS159 and cisapride, on the in situ canine heart assessed by cardiohemodynamic and electrophysiological monitoring. Toxicol. Appl. Pharmacol., <b>152<\/b>, 261-269.","DOI":"10.1006\/taap.1998.8494"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Sugiyama, A. and Hashimoto, K. (2002): Effects of a typical I<sub>Kr<\/sub> channel blocker sematilide on the relationship between ventricular repolarization, refractoriness and onset of torsades de pointes. Jpn. J. Pharmacol., <b>88<\/b>, 414-421.","DOI":"10.1254\/jjp.88.414"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Sugiyama, A., Satoh, Y., Takahara, A., Ando, K., Wang, K., Honsho, S., Nakamura, Y. and Hashimoto, K. (2004): Electropharmacological effects of a spironolactone derivative, potassium canrenoate, assessed in the halothane-anesthetized canine model. J. Pharmacol. Sci., <b>96<\/b>, 436-443.","DOI":"10.1254\/jphs.FPJ04025X"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Tsukada, A., Suemizu, H., Murayama, N., Takano, R., Shimizu, M., Nakamura, M. and Yamazaki, H. (2013): Plasma concentrations of melengestrol acetate in humans extrapolated from the pharmacokinetics established in <i>in vivo<\/i> experiments with rats and chimeric mice with humanized liver and physiologically based pharmacokinetic modeling. Regul. Toxicol. Pharmacol., <b>65<\/b>, 316-324.","DOI":"10.1016\/j.yrtph.2013.01.008"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Van de Water, A., Verheyen, J., Xhonneux, R. and Reneman, R.S. (1989): An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J. Pharmacol. Methods., <b>22<\/b>, 207-217.","DOI":"10.1016\/0160-5402(89)90015-6"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Wenzel-Seifert, K., Wittmann, M. and Haen, E. (2011): QTc prolongation by psychotropic drugs and the risk of torsade de pointes. Dtsch. Arztebl. Int., <b>108<\/b>, 687-693.","DOI":"10.3238\/arztebl.2011.0687"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Wilting, I., Smals, O.M., Holwerda, N.J., Meyboom, R.H., de Bruin, M.L. and Egberts, T.C. (2006): QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine. Am. J. Psychiatry., <b>163<\/b>, 325.","DOI":"10.1176\/appi.ajp.163.2.325"},{"key":"38","unstructured":"Wouters, W. and Deiman, W. (1983): Acute cardiac effects of fluvoxamine and other antidepressants in conscious rabbits. Arch. Int. Pharmacodyn. Ther., <b>263<\/b>, 197-207."},{"key":"39","doi-asserted-by":"crossref","unstructured":"Yamashita, M., Suemizu, H., Murayama, N., Nishiyama, S., Shimizu, M. and Yamazaki, H. (2014): Human plasma concentrations of herbicidal carbamate molinate extrapolated from the pharmacokinetics established in<i> in vivo<\/i> experiments with chimeric mice with humanized liver and physiologically based pharmacokinetic modeling. Regul. Toxicol. Pharmacol., <b>70<\/b>, 214-221.","DOI":"10.1016\/j.yrtph.2014.06.028"}],"container-title":["The Journal of Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/40\/1\/40_33\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T13:12:38Z","timestamp":1747228358000},"score":1,"resource":{"primary":{"URL":"http:\/\/jlc.jst.go.jp\/DN\/JST.JSTAGE\/jts\/40.33?lang=en&from=CrossRef&type=abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2131\/jts.40.33","relation":{},"ISSN":["0388-1350","1880-3989"],"issn-type":[{"value":"0388-1350","type":"print"},{"value":"1880-3989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}